<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002651</url>
  </required_header>
  <id_info>
    <org_study_id>ML5282</org_study_id>
    <nct_id>NCT01002651</nct_id>
  </id_info>
  <brief_title>In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects (Adults)</brief_title>
  <official_title>In Vivo Evaluation of the Physiological Effects of Arabinoxylan-oligosaccharides (AXOS) in Healthy Subjects: a Randomized, Placebo-controlled, Double-blind, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fugeia NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fugeia NV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigational study product used in this clinical trial is a soft drink containing an&#xD;
      arabinoxylan-oligosaccharides (AXOS) preparation extracted from wheat bran (hereafter called&#xD;
      Wheat Bran Extract, WBE).&#xD;
&#xD;
      The objective of this study is to analyze the effect of the intake of two WBE doses on&#xD;
      various parameters of gastrointestinal health. Additionally, safety was analyzed using&#xD;
      treatment emergent Adverse Events (AEs) and clinical blood parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bifidobacteria content in feces</measure>
    <time_frame>day 19 or 20 of each intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>butyric acid content in feces</measure>
    <time_frame>day 19 or 20 of each intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>p-cresol content in urine</measure>
    <time_frame>day 19-21 of each intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>stool frequency</measure>
    <time_frame>third week of each intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>whole study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical blood parameters</measure>
    <time_frame>day 21 of each intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Wheat Bran Extract (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wheat Bran Extract (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>wheat bran extract</intervention_name>
    <description>soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner</description>
    <arm_group_label>Wheat Bran Extract (high dose)</arm_group_label>
    <arm_group_label>Wheat Bran Extract (low dose)</arm_group_label>
    <other_name>arabinoxylan-oligosaccharides (AXOS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-90 years of age, inclusive&#xD;
&#xD;
          -  Regular eating habits&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 and 30 kg/m2&#xD;
&#xD;
          -  Consent to take in the study product according to the study protocol&#xD;
&#xD;
          -  Subject is willing to maintain his or her habitual food and beverage intake throughout&#xD;
             the study period (with the exception of omission of prebiotic and probiotic food&#xD;
             products as indicated in the study protocol)&#xD;
&#xD;
          -  For female volunteers of childbearing potential: not planning to become pregnant&#xD;
             during the clinical trial and willing to commit to the use of a medically approved&#xD;
             form of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Low-calorie diet or other extreme dietary habits in the 6 weeks before the start of&#xD;
             the clinical trial&#xD;
&#xD;
          -  Recent use of antibiotics&#xD;
&#xD;
          -  Abdominal surgery in the past&#xD;
&#xD;
          -  Serious illness within 3 months of start of clinical trial&#xD;
&#xD;
          -  Use of medication or dietary supplements known to influence GI tract within two weeks&#xD;
             of start of clinical trial. Examples of such medication/dietary supplements are&#xD;
             antispasmodics, anti diarrhea medication and/or probiotic medication&#xD;
&#xD;
          -  Complete anesthetics within 1 month of the start of the clinical trial&#xD;
&#xD;
          -  Chronic GI conditions such as inflammatory bowel disease (IBD), inflammatory bowel&#xD;
             syndrome (IBS), chronic constipation, history of frequent diarrhea, clinically&#xD;
             important lactose intolerance&#xD;
&#xD;
          -  Allergy for wheat products&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  For female volunteers: pregnant or lactating&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Smoking more than 5 cigarettes per day&#xD;
&#xD;
          -  Subject has a condition the Investigator believes would interfere with his or her&#xD;
             ability to provide informed consent, comply with the study protocol, which might&#xD;
             confound the interpretation of the study results or put the subject at undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Willem Broekaert, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Fugeia NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastrointestinal Research, Laboratory Digestion and Absorption</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>October 26, 2009</last_update_submitted>
  <last_update_submitted_qc>October 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kristin Verbeke, Ph.D.</name_title>
    <organization>Katholieke Universiteit Leuven</organization>
  </responsible_party>
  <keyword>gastrointestinal health</keyword>
  <keyword>healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

